Foundation Medicine, Incyte Partner on CDx Development

Sep 11, 2018

NEW YORK (GenomeWeb) – Foundation Medicine and Incyte have partnered to develop and commercialize companion diagnostics, the companies said today.

The initial focus will be on developing a CDx for Incyte's FGFR1/2/3 inhibitor, pemigatinib, to treat patients with cholangiocarcinoma. This will include the detection of activating FGFR2 translocations. The companies expect to incorporate the CDx into Foundation Medicine's existing US Food and Drug Administration-approved assay, FoundationOne CDx.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Featured White Papers

Sampling for Optimal cfDNA Extraction

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Discovering Neuronal Cell Types

How to Use CrownBio's Integrated Oncology Portfolio for Target Identification and Mechanism of Action Elucidation

Dec

03

Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec

04

Featured Webinar

Clinical-Grade Exome Analysis for Complex and Unsolved Case Investigations

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec

06

Featured Webinar

Mapping The Disease-Variant Landscape To Accelerate Precision Drug Development

Rhythm Pharmaceuticals and Genomenon will discuss their efforts to assemble a database of mutations associated with rare genetic disorders of obesity, and how this was optimized to facilitate a deep understanding of the variant landscape of melanocortin-4 receptor (MC4R)-pathway genes. This database may help identify MC4R-pathway deficient individuals who might benefit from future precision therapies.

Main menu